Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer. Its platforms include analysis of single biomarkers using the polymerase chain reaction method as well as global gene interrogation using microarray methods from paraffin or frozen tissue specimens. It also provides pharmacogenomic testing services of clinical trial specimens to pharmaceutical companies. The company was founded by David A. Smith and Kathleen Danenberg on September 23, 1999 and is headquartered in Los Angeles, CA.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company